"CSCO- Redding Clinical Tumor New Progress Summit Forum" held, the big curry theory of drug innovation

"Over the past decade, the central government has invested nearly 20 billion yuan to support the innovation and development of biopharmaceuticals in China, with more than half of the investment in innovative drugs. This year is the year of the '13th Five-Year Plan' and the year of the '14th Five-Year Plan'. Since the implementation of the special, nearly 60 new class 1 drugs have been approved. Chen Kai, a member of the Chinese Academy of Sciences and deputy general manager of major national science and technology special technology for the creation of major new drugs, first pointed out at the 2nd "CSCO-Reeding Summit Forum on New Progress in Clinical Oncology".
12 years, nearly 60 class 1 innovative drugs have been approved, and Chinese patients have used domestically produced good medicines
In the recently announced 14th Five-Year Plan and the 2035 Vision, the Central Committee clearly proposed to "comprehensively promote the construction of a healthy China" and move towards the "front of an innovative country".
Chinese Academy of Sciences academician, major new drug creation of the country's major science and technology special technical deputy general division Chen Kai first pointed out at the forum, since the implementation of the special, there have been nearly 60 new drugs of the first class approved, to fill the relevant disease areas of drug use gaps, to solve the people's major disease drug demand, alleviate the people's "expensive to see a doctor" problem provides a strong support. It is hoped that in the future, through the "major new drug creation" technology major special incentive mechanism, so that more local enterprises strive to develop suitable for Chinese patients diagnosis and treatment programs, from a fundamental change in the treatment pattern of Chinese patients.
Professor Qin Shuxuan, Vice President of the Chinese Society of Clinical Oncology (CSCO) and Director of the Oncology Center of Jinling Hospital in Nanjing, said: "In recent years, the trend of innovative research and development in China has been evident to all, and clinical trials have been successful, making significant contributions to the clinical treatment strategy and practice of tumors. It is hoped that more and more enterprises can adopt different strategies to develop more abundant and innovative drugs, provide more kinds of drugs for Chinese patients, better quality and benefit from longer survival, and accelerate the process of 'going out' in the research and development of new anti-cancer drugs in China.
With 16 more products and drug candidates, layout a variety of oncology areas
in the context of the country's continued encouragement of independent innovation in biopharmaceuticals, Reding already has two products for 3 adaptive disorders approved for market, one product has been included in the priority review of new drug market applications, in China and the world is being carried out or planned to carry out more than 25 cancer clinical trials.
At this meeting, Reding Pharmaceuticals demonstrated differentiated and widely validated product pipelines, and Dr. Du Ying, Chairman and CEO of Reding Pharmaceuticals, said, "As an important member of the new force of innovative medicine in China, Reding has established a portfolio of 16 products and drug candidates, especially in the field of women's tumors, neuro-tumors, gastrointestinal tumors, blood tumors and other treatments with huge gaps in medical needs but lack of innovative treatment options." We already have two independently developed, global intellectual property candidates entering the clinical research phase. In the future, we will continue to bring more innovative treatments to patients through independent research and development and international cooperation in two-wheel drive.
Focusing on the 2030 Healthy China National Strategy and Building the Frontiers of Hainan International Pharmaceutical Technology
In September 2019, several ministries and departments jointly issued the Implementation Plan on Supporting the Construction of the Boao Lecheng International Medical Tourism Advance Zone, giving the Lecheng Advance Zone a new special policy on drug supervision. In June this year, after the release of the "General Plan for the Construction of Hainan Free Trade Port", Lecheng Advance District created a number of national firsts in terms of new drugs, new equipment, new technology approval and introduction.
In July of this year, the re-ding gastrointestinal mesothelioma target drug Ripaitini was introduced to Boao Super Hospital, which is the representative event of "first try" of innovative drugs since the announcement of Hainan Free Trade Port Policy in June, achieving three "first" historical breakthroughs: the first simultaneous use of new drugs in China and the world; In November, at the 3rd China Import Expo, Reding Pharmaceuticals and Lecheng Advance District Administration, China Clinical Oncology Foundation and Hainan First Chengmei Medical Industry Group signed a strategic cooperation agreement to jointly build an "advanced cancer treatment center."
Zhefeng, deputy director of the International Medical Tourism Advance District Administration of Boao Lecheng, Hainan Province, said: "Lecheng Advance District has landed many of the world's advanced treatment programs. With more and more patients coming to the area in the future, we are eager to work with clinical experts and local innovative pharmaceutical companies in-depth cooperation, and constantly improve the level of clinical diagnosis and treatment of tumors, the establishment of standardized treatment concept, for patients to bring more sense of access. "
。